Potassium sparing diuretic (DrugBank: Potassium)
10 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
36 | 表皮水疱症 | 0 |
46 | 悪性関節リウマチ | 0 |
66 | IgA腎症 | 0 |
67 | 多発性嚢胞腎 | 0 |
98 | 好酸球性消化管疾患 | 0 |
115 | 遺伝性周期性四肢麻痺 | 0 |
167 | マルファン症候群 | 0 |
179 | ウィリアムズ症候群 | 0 |
215 | ファロー四徴症 | 0 |
235 | 副甲状腺機能低下症 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02824718 (ClinicalTrials.gov) | June 6, 2017 | 1/7/2016 | Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism | A Randomized Crossover TrIal to Compare Recombinant Human rhPTH(1-34) to the ASsociation Alfacalcidol/Hydrochlorothiazide in the Treatment of Severe Primary Hypoparathyroidism | Autosomal Dominant Hypocalcemia or OR Primary Hypoparathyroidism Related to Other Cause But Complicated by Hypercalciuria Under Treatment | Drug: Teriparatide;Drug: Thiazide;Drug: Potassium sparing diuretic;Drug: Alfacalcidol | Assistance Publique - Hôpitaux de Paris | Ministry of Health, France | Recruiting | 18 Years | 80 Years | All | 12 | Phase 2 | France |